Manabu Morimoto

Kanagawa Cancer Center ORCID: 0000-0002-3940-9634

1

h-index

1

Publications

1,593

Citations

Publications

1 shown

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

2019 The Lancet Oncology 1593 citations

Frequent Co-Authors

Andrew X. Zhu

Harvard University

Yoon‐Koo Kang

Asan Medical Center

Chia‐Jui Yen

National Cheng Kung University

Richard S. Finn

UCLA Jonsson Comprehensive Cancer Center

Peter R. Galle

European Association for the Study of the Liver

Josep M. Llovet

European Association for the Study of the Liver

Researcher Info

h-index: 1
Publications: 1
Citations: 1,593
Institution: Kanagawa Cancer Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-3940-9634

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.